Literature DB >> 24815446

Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.

Hong-Li Wang1, Mei-Mei Liu, Xin Ma, Lei Fang, Zong-Feng Zhang, Tie-Fang Song, Jia-Yin Gao, Ye Kuang, Jing Jiang, Lin Li, Yang-Yang Wang, Pei-Ling Li.   

Abstract

Previous studies have demonstrated that JMJD2A is a potential oncogene and is overexpressed in human tumors. However, its role in the endometrial carcinoma remains largely unknown. In this study, we discovered that JMJD2A was overexpressed in endometrial carcinoma, using immunohistochemistry, quantitative real- time polymerase chain reaction, and western blotting. Downregulation of JMJD2A led to reduced endometrial carcinoma RL95-2 and ISK cell proliferation, invasion and metastasis as asessed with cell counting kit-8, cell migration and invasive assays. Collectively, our results support that JMJD2A is a promoter of endometrial carcinoma cell proliferation and survival, and is a potential novel drug target.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24815446     DOI: 10.7314/apjcp.2014.15.7.3051

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

Review 1.  Critical roles of non-histone protein lysine methylation in human tumorigenesis.

Authors:  Ryuji Hamamoto; Vassiliki Saloura; Yusuke Nakamura
Journal:  Nat Rev Cancer       Date:  2015-02       Impact factor: 60.716

2.  SUMO modification of a heterochromatin histone demethylase JMJD2A enables viral gene transactivation and viral replication.

Authors:  Wan-Shan Yang; Mel Campbell; Pei-Ching Chang
Journal:  PLoS Pathog       Date:  2017-02-17       Impact factor: 6.823

3.  Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.

Authors:  Jingyi Zhao; Bingyan Li; Yongxia Ren; Tiansong Liang; Juan Wang; Suna Zhai; Xiqian Zhang; Pengcheng Zhou; Xiangxian Zhang; Yuanyuan Pan; Fangfang Gao; Sulan Zhang; Liming Li; Yongqiang Yang; Xiaoyu Deng; Xiaole Li; Linhui Chen; Daoke Yang; Yingjuan Zheng
Journal:  Exp Mol Med       Date:  2021-08-12       Impact factor: 8.718

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.